MADRIGAL PHARMACEUTICALS, INC.
WEST CONSHOHOCKEN, PA · CIK 0001157601 · Biotech · Public
Small molecule therapeutic for metabolic dysfunction-associated steatohepatitis (MASH)
madrigalpharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $35M
- 1 Form D · Jul 2017
- 111 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 16 granted · 24 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2017
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $35,000,018 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1212 | Dianomi Therapeutics, Inc. | — | $185K |
| 1213 | Novoglia, Inc. | — | $37M |
| 1214 | Matrubials, Inc. | — | — |
| 1215 | MADRIGAL PHARMACEUTICALS, INC. | — | $35M |
| 1216 | OS Therapies Inc | — | $30M |
| 1217 | Universal Ibogaine Inc. | — | $135K |
| 1218 | Willowcroft Pharm Inc | — | $5.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Kenneth BateDirector
- Fred CravesDirector
- Paul FriedmanDirector · Executive Officer
- Keith GollustDirector
- Richard LevyDirector
- David MilliganDirector
- Marc SchneebaumExecutive Officer
- Rebecca TaubDirector
Patents
- Methods For Treating A Fatty Liver Diseasegranted
- Therapeutic Combinations Of Rosuvastatin And Resmetirom For The Treatment Of Liver Disorders Or Lipid Disordersgranted
- Resmetirom For Reducing Liver Volumegranted
- Solid Forms Of 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILEapplication
- Methods For Treating A Fatty Liver Diseasegranted
- Novel Thr Beta Analogs And Uses Thereofapplication
- Solid Forms Of 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILEapplication
- Biomarkers For Treating Liver Disorders With Thr-b Agonists And Related Usesapplication
- Resmetirom For Reducing Liver Volumeapplication
- Methods Of Treating Liver Disorders Or Lipid Disorders With A Thr-beta Agonistapplication
- Methods For Preparing Pyridazinone Derivativesapplication
- Methods Of Treating Liver Disorders Or Lipid Disorders With A Thr-beta Agonistgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.